Abrysvo™ (respiratory syncytial virus vaccine) – New indication
August 21, 2023 - The FDA announced the approval of Pfizer’s Abrysvo (respiratory syncytial virus vaccine), for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age
Top